Navigation Links
ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures
Date:9/30/2009

PITTSBURGH, Sept. 30 /PRNewswire/ -- ThermalTherapeutic Systems, Inc., developers of a highly portable platform technology to standardize hyperthermic perfusion announced today the completion of $2.75 Million Series A financing.

After receiving initial start-up funding by the Pittsburgh Life Sciences Greenhouse, and successful rounds of private financing which included follow-on investments by the Pittsburgh Life Sciences Greenhouse and Innovation Works, Originate Ventures has taken the lead on a $2.75 million commitment intended to spearhead the commercialization of ThermalTherapeutic Systems proprietary new technology.

"Originate Ventures' financial support of our strategic objectives marks a significant milestone in our company's development. In July we submitted our application to the FDA, in August we closed on $750,000 in private financing and, in September, Originate Ventures recognized that their investment would be the catalyst to launch our technology," said Raymond F. Vennare, Co-Founder and CEO. "For physicians, the possibility now exists to provide better treatment options for a growing number of patients and, for investors, an opportunity to participate in a potential billion dollar growth market with international implications."

"ThermalTherapeutic Systems not only fits our investment profile," said Mike Gausling, Managing Partner of Originate Ventures, "but promises to be a disruptive technology in an emerging market; it addresses an unmet need in the marketplace and anticipates future applications for hyperthermic perfusion."

"We are pleased to be able to partner with Originate Ventures, and recognize the positive impact their investment will have in enabling ThermalTherapeutic Systems to provide physicians and hospitals with a powerful and innovative new tool to treat patients," stated Peter M. DeComo, Co-founder and Chairman of ThermalTherapeutic Systems.

About ThermalTherapeutic Systems: www.thermaltherapeutics.com

ThermalTherapeutic Systems, Inc. is in the final stages of development of a portable hyperthermic perfusion system. The intended use of the TTS100 Portable Hyperthermic Perfusion Device is to raise the temperature of the thoracic or peritoneal cavity. This proprietary technology is designed to provide the medical community with a small, portable, and lightweight device, which has been specifically designed to standardize the use and improve the control of hyperthermic and normalthermic perfusion.

About Originate Ventures: www.originateventures.com

Originate Ventures is a venture capital firm with offices in Bethlehem, PA targets early stage product and services companies in Pennsylvania and surrounding regions. The firm focuses on opportunities in the information technology, healthcare, consumer, Web-based and certain commercial product and distribution fields. Operating with an entrepreneurial spirit and vision, Originate's investments range in size from $1,000,000 to $4 million.

SOURCE ThermalTherapeutic Systems, Inc.


'/>"/>
SOURCE ThermalTherapeutic Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
2. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
3. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
4. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
5. Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
6. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
7. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
8. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
9. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
10. PLC Systems Reports Fourth Quarter 2007 Results
11. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017 - First major agreements signed with ... expected to grow by a CAGR of approximately 6-9% between ... company which operates globally across a number of sectors, announces that ... notable successes and is well-positioned for further expansion within the rapidly ... ...
(Date:1/17/2017)... , Jan. 17, 2017  Allergan Plc (NYSE: ... from Venus II, the second of two pivotal phase III ... in women with abnormal bleeding due to uterine fibroids.  A ... the second half of 2017. "We are pleased ... and safety profile of ulipristal acetate as shown in our ...
(Date:1/16/2017)... Research and Markets has announced the addition of the "Global ... ... drugs market to grow at a CAGR of 9.19% during the ... and the growth prospects of the global multiple myeloma drugs market ... revenue generated from the sales of branded and generic drugs used ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Etymotic Research, makers ... and EB15•LE® electronic earplugs at the NSSF SHOT Show on January 17-20, 2017 ... SHOT Show is the shooting, hunting and outdoor trade show and conference for ...
(Date:1/16/2017)... ... January 16, 2017 , ... Houston dentist, Dr. Behzad Nazari, ... complimentary consultations and financing for orthodontics for a limited time. Complimentary for a ... about their orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments are available. Antoine ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... audit protocols to understand the scope of their EHS regulatory obligations and rapidly ...
(Date:1/16/2017)... ... January 16, 2017 , ... Date ... http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, researcher and advocate ... syndicated radio program, The Sharon Kleyne Hour Power of Water, Global Climate Change ...
(Date:1/16/2017)... ... January 16, 2017 , ... One thing common to all ... but to test for, as well. The money spent screening for and treating cancer ... the U.S. screen patients for cancer more than in any other country that has ...
Breaking Medicine News(10 mins):